Astellas Pharma Global Development

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Astellas Pharma Global Development sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).

168 total trials 19 currently recruiting 121 completed early-phase tilt top decile by trial count

Astellas Pharma Global Development: 168 sponsored US clinical trials, 19 recruiting.

Astellas Pharma Global Development sponsors 168 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 121 completed. 28 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 10 trials.

Top-decile sponsor footprint

Astellas Pharma Global Development ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 57/100

121 of 139 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

168 total, page 4 of 4

COMPLETED Phase 1

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

NCT01651325

COMPLETED Phase 1

Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects

NCT01657838

COMPLETED Phase 1

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

NCT02171143

COMPLETED Phase 1

Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone

NCT01597986

COMPLETED Phase 1

Drug Interaction Study of Isavuconazole and Methadone

NCT01582425

COMPLETED Phase 1

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

NCT01529684

COMPLETED Phase 1

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

NCT01565720

COMPLETED Phase 1

Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.

NCT01555866

COMPLETED Phase 1

A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects

NCT01711489

COMPLETED Phase 1

Drug Interaction Study of Isavuconazole and Digoxin

NCT01582412

COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects

NCT01711827

COMPLETED Phase 1

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

NCT01582399

COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects

NCT01809860

COMPLETED Phase 1

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070

COMPLETED Phase 1

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

NCT02125435

COMPLETED Phase 1

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

NCT01998646

COMPLETED Phase 1

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

NCT01565681

COMPLETED Phase 1

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

NCT01678287

← Previous Page 4 of 4

What is open in the Astellas Pharma Global Development pipeline

19 recruiting of 168 indexed (11% open); 121 completed (72%).

Phase mix: 28 late (III/IV) vs 132 early (I/II) (early-phase heavy).

Top condition: Healthy Volunteers (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Astellas Pharma Global Development: open-pipeline peers nationwide

Peers matched on 168 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Astellas Pharma Global Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 100120140160180200 0%5%10%15%20% Total trials Recruiting share Astellas Pharma Global DevelopmentBausch Health AmericasSeattle Children's HospitalSumitomo Pharma AmericaUniversity of New MexicoSt. Louis UniversityUniversity of ConnecticutChildren's Mercy Hospital Kansas CityAlbert Einstein College of Medicine
Astellas Pharma Global Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Astellas Pharma Global Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 168 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Astellas Pharma Global Development page

168 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma Global Development or any single study.

  • 19 of Astellas Pharma Global Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Volunteers is the condition Astellas Pharma Global Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Astellas Pharma Global Development pipeline card: 168 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.